News|Slideshows|March 25, 2021

8 Neuropsychiatric Symptoms and Treatments of Huntington Disease

Author(s)Rajesh R. Tampi, MD, MS, DFAPA, DFAAGP, Monica Weber, MBA, MSSA, CCTP, LISW-S, Gilbert A. Masterson, MD

In approximately half of patients with Huntington disease, symptoms of depression, irritability/aggression, executive dysfunction, psychosis, cognitive decline, and dementia present long before progressive motor symptoms.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Metabolic Risk, Residual Insomnia, and Seltorexant

ByJane Tiller, MD

June 25th 2026

Seltorexant as Adjunctive Therapy for MDD With Insomnia

ByJane Tiller, MD

June 24th 2026

Psychiatric Comorbidities in Adults With Congenital Heart Disease and the Need for Interdisciplinary Care

BySophia Hashmi,Hazem Shahin, MD

June 24th 2026

Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder

ByLeah Kuntz

June 22nd 2026

GABA Deficits and Sleep Disruption in Early Alzheimer Disease

ByKsenia Kastanenka, PhD

June 15th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

8 Neuropsychiatric Symptoms and Treatments of Huntington Disease

Related Content

Metabolic Risk, Residual Insomnia, and Seltorexant

Seltorexant as Adjunctive Therapy for MDD With Insomnia

Psychiatric Comorbidities in Adults With Congenital Heart Disease and the Need for Interdisciplinary Care

Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder

GABA Deficits and Sleep Disruption in Early Alzheimer Disease

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder

Phase 2 Analysis of ML-004 for Autism Spectrum Disorder Fails to Meet Endpoint

Psychiatric Pharmacogenomics: An Overview

Celebrating the First APA Panel of Transgender Psychiatrists of Color: A Conversation With Emrys Fonseca, MD, MS

Preventing Relapse in Schizophrenia: Focus on Women’s Mental Health